Genmab (GMAB) and Incyte (INCY) said Saturday they agreed to test petosemtamab with Incyte's treatment plus standard chemotherapy as a first-line treatment for metastatic colorectal cancer with a specific KRAS mutation.
Genmab will run the phase 1/2 study and Incyte will co-fund it and supply its treatment drug, the companies said.
Petosemtamab is an experimental bispecific antibody targeting the EGFR and LGR5 proteins, and Incyte's treatment blocks the KRAS mutation found in about 40% of colorectal cancers, they said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments